Articles On Orthocell (ASX:OCC)

Tylah Tully chats with Orthocell (ASX:OCC) CEO and managing director Paul Anderson after a new real-world study demonstrated a 81.1% treatment success rate for the company’s nerve repair device, Remplir. Anderson explains why this real-worl...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Data to support US sales roll out and EU + UK regulatory submissions  Interim resu...

ASX closes 0.24% lower on Monday with tech leading gainers and energy the laggards Asian markets climb higher led by Tokyo after Japanese Prime Minister Shigeru Ishiba announces resignation Supermarket giants Coles and Woolworths face heft...

Interim results from Orthocell’s new Remplir study demonstrate treatment success rate of 81.1% following nerve repair procedures Results confirm Remplir as ideal for connecting severed nerves, protecting damaged nerves or capping nerves af...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully looks at Orthocell (ASX:OCC), whose nerve repair product Remplir is continuing its strong US market momentum with increa...

Avita shares jump up to 13% after the company’s $23 million equity raising   EBR Systems narrows June quarter loss Orthocell is on track with its US rollout   Burns and woundcare outfit Avita Medical (ASX:AVH) has answered concerns about...

Despite myriad pressures under the Trump regime, the FDA’s drug and device approval process largely has been unfettered Telix Pharmaceuticals expects a company-making approval decision by the end of the month Painchek is among a string of...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights Orthocell announces director resignation due to health, maintains advisory support Lanthanein completes drilling phase at Lady Grey Project in Western Australia Aurum and Asian Battery Metals report progress acros...

  Experienced corporate leader Michael McNulty will join the board as a non-executive director and chair of audit committee US-based independent non-executive director Dr Ravi Thadhani elevated to lead independent director Former oppositio...

Former WA governor and US ambassador Kim Beazley will step down from the board of Perth regenerative medicine company Orthocell due to health reasons.

ASX industrials shares grew significantly in FY 25. The S&P/ASX 200 Industrials Index (ASX: XNJ) is up almost 10% since January.  Broker Bell Potter has identified two ASX industrials shares that are currently undervalued, placin...

Evolution Mining Ltd (ASX: EVN) shares have been very strong performers over the past 12 months. In fact, the ASX 200 gold stock has rocketed approximately 90% since this time last year. This has almost doubled its market capitalisation to...

DroneShield Ltd (ASX: DRO) shares are starting the week with a bang. In morning trade, the counter drone technology company's shares are up over 11% to a new record high of $3.09. Why are DroneShield shares rocketing? Investors have been bi...

On Thursday, the S&P/ASX 200 Index (ASX: XJO) had a good session and charged higher. The benchmark index rose 0.6% to 8,589.2 points. Will the market build on this on Friday and end the week on a high? Here are five things to watch: ASX...

Highlights Novo Resources identifies high-grade gold intercepts at Tibooburra Gold Project in NSW Orthocell reports record FY2025 revenue, advancing regenerative medicine footprint Resolution Minerals gears up for major dril...

ASX shrugs off tariff pessimism to climb 0.59pc Gains led by gold and banking stocks Major banks join RBA stablecoin project   Gold and Banks lead ASX charge Let’s see – a 50% tariff on copper, up to 200% on pharmaceuticals, and maybe mor...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully takes a look at Orthocell (ASX:OCC), who have achieved first US revenue from Remplir, its flagship nerve repair product,...

Good Afternoon and welcome to HotCopper’s Market Close for Thursday 10th of July, I’m Jon Davidson.  It was a green day at least, but still below 8,600 points, we’re yet to return to recent glories. The big thing to note in my view is th...

Trigg Minerals (ASX:TMG) has drawn the most attention on the HotCopper forums through Thursday trade after the mining company mysteriously halted just before open. Holders were left “a bit worried” across the boards. Listen to the HotCop...

Platinum Asset Management Ltd (ASX: PTM) shares are having a day to remember on Thursday. In afternoon trade, the fund manager's shares are up 13% to 56 cents. Why are Platinum shares rocketing? Investors have been scrambling to buy the com...

The S&P/ASX 200 Index (ASX: XJO) is back on form and charging higher on Thursday. In afternoon trade, the benchmark index is up 0.8% to 8,607.4 points. Four ASX shares that are rising more than most today are listed below. Here's why th...

The Australian share market is back on form on Thursday. In morning trade, the All Ordinaries index is up 0.5% to 8,823.2 points. One ASX All Ords stock that is outperforming the index is named below. Let's see why its shares are jumping to...

The boss of WA regenerative medicine company Orthocell has labelled Donald Trump’s latest tariff threat on pharmaceuticals as a ‘cage-rattling exercise’ to try elicit panic from the Australian Government.

POTUS threatens a foreign drug tariff, but gives Big Pharma more time to shift production onshore ASX drug makers say they won’t be overly affected by any Trump tariff whack Island Pharma acquires a secondary virus program   Donald Trump...

Regenerative medicine company Orthocell (ASX: OCC) has reported a record revenue of $9.19 million for the 12 months to the end of June 2025, underscoring market penetration and sales growth of its flagship nerve repair product Remplir in Au...

Highlights  Copper prices soar after tariff announcement  ASX 200 opens soft following RBA decision  Small-cap mining and tech news draws focus  The Australian share market opened softer today as investors reacted to global trade...

Orthocell is staging the US rollout of its Remplir device, including “pausing” enlisting too many distributors at once In Remplir’s first US commercial usage, an Ohioan surgeon has deployed the device successfully More than 300 investors t...

Australian companies can be the source of significant passive income if investors selectively choose the right stocks. ASX blue-chip shares can fully frank their dividends due to Australia's taxation system, resulting in larger grossed-up d...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Highlights Lithium Universe advances with key acquisition in photovoltaic recycling technology. Surefire Resources intersects sulphides at Yidby Gold Project. St George Mining begins new geophysical work at Brazilian rare ea...

ASX-listed healthcare companies have long had an outsized impact on global markets. Think CSL Ltd (ASX: CSL), ResMed Inc (ASX: RMD), and Cochlear Ltd (ASX: COH). For shareholders who got in it early with those companies, the rewards h...

BHP Group Ltd (ASX: BHP) shares feature in countless investment portfolios and superannuation funds across the country. As a result, the performance of the mining giant's shares has a big impact on the wealth of Australians. But was this im...

WA biotech Orthocell has posted record revenue for the June quarter as sales for its nerve repair technology surge in Australia, ahead of an expected ramp up in US.

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is down 0.15% to 8,555.2 points. Four ASX shares that are rising more than most today are listed below...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Orthocell Ltd (ASX: OCC) shares are starting the month on a positive note. In morning trade, the ASX All Ords stock is up 7% to $1.26. Why is this ASX All Ords stock jumping? The catalyst for today's gain has been the release of a sales upd...

Highlights  ASX 200 likely to open slightly lower despite Wall Street gains  Trade optimism lifts global equities and supports commodities  Small caps see active corporate developments and funding updates  The Australian share mar...

Tetratherix’s listed life starts on a solid note Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come Orthocell chalks up first commercial US procedure for its Remplir device Today’s ASX debut of wound management...

WA regenerative medicine firm Orthocell says it has marked another commercialisation milestone with the first successful surgical use of its nerve repair product in the US.

Good Afternoon and welcome to HotCopper Highlights for the end of Week 26, I’m Jon Davidson. In this segment, the stocks you were watching and discussing most this week, let’s get into it starting with the most viewed.  Trigg Minerals ma...

Orthocell (ASX:OCC) shares have notched upwards on Friday before lunchtime as the company announced its nerve repair product had been used successfully in a U.S.-based surgery for the first time. Listen to the HotCopper podcast for in-de...

Regenerative medicine company Orthocell (ASX: OCC) has achieved a major breakthrough in the global development of its Remplir technology with the successful completion of a first surgery in the US. Doctors at a hospital in Ohio used the com...

Highlights  ASX200 slips slightly as IT sector weighs on index  Lithium and resource stocks show upward momentum  US data fuels rate cut expectations, impacting global markets  The ASX 200 index edged lower on Thursday, closing do...

ASX falls 8.4 points, which was about 0.1% Xero sheds 4.7% on $3.9b acquisition of Melio Payments Info tech sector slumps 2%   ASX edges lower on Xero acquisition The ASX 200 has fallen 8.4 points or 0.1% in trade today, after major infor...

Botanix Pharmaceuticals (ASX:BOT) CEO Dr Howie McKibbon says investors shouldn’t rely just on management’s assertion that its anti-sweating drug Sofdra has – and we paraphrase – “the potential to be the world’s most successful dermatology d...

Orthocell says its Remplir nerve device blitzes the stitches Singular Health inks US physician network deal Clarity clearly is undervalued, say brokers   Among other auspicious events, the 19th of June marks the end of slavery in the US,...

A new study shows Orthocell’s Remplir product results in superior generation of nerve tissue and earlier return of muscle function The product allows surgeons to reduce the number of sutures required to reconnect severed nerves Existing c...